EngramBio
Restore, repair, remember
Preserve the memories that shape our identity and quality of life
Through advanced neuroscience and cutting-edge technology, we're developing innovative approaches to restore neural pathways, repair damaged connections, and help patients remember what matters most.
ABOUT
Bridging Neuroscience and AI Innovation
At EngramBio, we combine our neuroscience expertise with cutting-edge artificial intelligence to transform how neurological therapeutics are discovered and developed. Our platform accelerates the traditionally lengthy drug discovery process, bringing hope to patients faster than ever before. By integrating human induced pluripotent stem cell-derived neurons with state-of-the-art machine learning, computational biology, and advanced neural modeling, we create patient-relevant systems that more accurately predict therapeutic success. Using these technologies, EngramBio is working to repair synapses, restore brain health, and help people remember. Our mission is to find a cure for Alzheimer's disease and other dementias, because we believe memory loss isn't inevitable, and reversing cognitive decline can become a reality.
TECHNOLOGY
Our Core Technology platform
A three-step integrated approach combining laboratory science with artificial intelligence.
Laboratory & AI Target Validation
Comprehensive validation using wet lab experiments and computational models. High-confidence target identification with reduced false positives
AI In Silico Screening
Virtual compound libraries screened using advanced ML algorithms. Millions of compounds evaluated in hours instead of years.
Drug Validation
Multi-modal validation combining computational and experimental approaches. Optimized candidates ready for clinical development.
AWARDS & PARTNERSHIPS
NIH NIA Startup Challenge Finalist
Stimulating aging innovation for early stage entrepreneurs with innovative ideas for technologies to improve healthy aging.
MEET THE TEAM
Kristeen A. Pareja-Navarro, PhD
CEO, Co-founder

Dr. Kristeen A. Pareja-Navarro, co-founder and CEO of EngramBio, leads the development of first-in-class therapeutics to repair neural connections in Alzheimer’s and related dementias. A former Research Scientist at the Buck Institute, she co-discovered the KIBRA domain’s ability to reverse memory loss in a tauopathy model. With 16+ years of neuroscience and biotech experience, an NSF Graduate Research Fellowship at Cornell, and training from MIT Sloan in AI for drug discovery, she bridges cutting-edge science with strategic leadership.

Tara E. Tracy, PhD.
Co-founder

Dr. Tara E. Tracy, co-founder of EngramBio and Associate Professor at the Buck Institute, is the inventor of the patented CT-KIBRA peptide, which forms the foundation of EngramBio’s lead program. Her discoveries have revealed how toxic mechanisms drive synapse dysfunction and memory loss in Alzheimer’s and related dementias, shaping new therapeutic strategies. A recipient of the McKnight Brain Research Foundation Innovator Award (2022) and Next Generation Bay Area Biotech Superstar (2024), she brings expertise in molecular neuroscience and translational research from UC Berkeley, and the Gladstone Institutes.

Ready to Transform Drug Discovery?
Join us in accelerating the development of life-changing neurological therapeutics.
Whether you're a pharmaceutical partner, investor, or research collaborator, let's discuss how we can work together to bring hope to patients worldwide.
Get In Touch